NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.190
+0.040 (3.48%)
Jan 3, 2025, 4:00 PM EST - Market closed
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 18 employees as of December 31, 2023. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$644,222
Market Cap
27.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
NRSN News
- 12 days ago - NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - PRNewsWire
- 17 days ago - NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - PRNewsWire
- 24 days ago - NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - PRNewsWire
- 4 weeks ago - NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - PRNewsWire
- 4 weeks ago - NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price - PRNewsWire
- 6 weeks ago - NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - PRNewsWire
- 2 months ago - NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - PRNewsWire
- 2 months ago - New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients - PRNewsWire